福泰制药(VRTX)今日盘前股价大涨8.35%,引发市场强烈关注。主要利好消息包括:
其新型非毒品止痛药Journavx获得美国FDA批准上市,这是数十年来首款新型非阿片类止痛药获批,被认为比阿片类止痛药更安全,避免了上瘾风险。全美阿片类药物滥用成为严重的公共卫生危机,该药物将为解决这一问题提供新的选择。
同时,福泰制药与CRISPR Therapeutics公司合作开发的用于治疗罕见遗传疾病镰状细胞病的基因疗法获英国政府批准纳入国民医保体系,每例疗程费用约210万美元。这一尖端治疗手段有望从根本上治愈镰状细胞病,市场需求前景广阔。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.